Date: 01-Oct-2019

US FDA issues 12 observations for Cipla's Goa manufacturing facility

Cipla Ltd announced that United States Food and Drug Administration (FDA) conducted a cGMP inspection at Goa manufacturing facility from September 16-27, 2019. The inspection ended with 12 observations, none of which are related to data integrity, the company said. The company said it will respond to the agency within the stipulated timeline.